NIH OKs embattled Boston biolab

The National Institutes of Health (NIH) gave its final approval yesterday for Boston University (BU) to build a research complex containing Biosafety Level 2, 3 and 4 laboratories on its medical campus in the city?s South End/Roxbury neighborhood. Construction on the seven-story National Emerging Infectious Diseases Laboratories (NEIDL) will begin early this month and should be completed by August 2008, BU officials announced yesterday in a staff memo."We are proud to now be part of the national network of dedicated scientists and researchers who will use this state-of-the-art facility to safely find treatments and cures for some of the most dangerous infectious diseases that threaten Boston, the nation, and the world," the lab?s principal investigator, Mark Klempner, said in the memo, of which The Scientist obtained a copy."NIAID is pleased that another milestone has been accomplished in Boston University's effort to construct a National Biocontainment Laboratory to conduct important research on infectious diseases," Rona Hirschberg, senior program officer in the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Disease (NIAID), said in a statement released yesterday (February 2).The biolab project has been controversial since September 2003, when NIAID chose Boston over other competing sites and promised $128 million toward the lab?s $178 million projected cost.Opponents claimed that research on Ebola and other incurable diseases should not be conducted in a congested urban environment. In April 2004, 146 Massachusetts university professors sent a letter to the mayor and BU?s trustees, saying the risk of human error or terrorist attacks was too great to accept.Controversy over the plan intensified in January 2005 when the university and the city revealed that three BU workers working in a lower-security lab had infected themselves with a lethal strain of tularemia the previous year, eventually recovering.NEIDL proponents?including BU?s acting medical campus provost Thomas Moore --claimed the tularemia accident is irrelevant, because researchers in the new facility will work in air-sealed moon suits in Biosafety Level four (BSL-4) labs, the most highly-engineered and secure facilities. The mayor and most of City Council support the lab, according to Klare Allen, spokesperson for Roxbury?s Safety Net, one of the groups leading the opposition. NIH says the project will provide 660 permanent jobs with a total annual income of $33 million.Opponents appear to be accepting defeat. "They will construct a building," Allen admitted. However, she and Sheldon Krimsky, a professor at Tufts University in Boston who also opposes the lab, said they plan to shift their efforts, concentrating on ensuring the lab is operated as safely as possible. "We?re going to make sure they dot every ?i? and cross every ?t?," Allen said, adding that the Boston Public Health Commission is also considering a comprehensive set of new regulations to govern all 1,000 biology labs in the city.John Dudley Miller johnmiller@nasw.orgLinks within this article National Emerging Infectious Diseases Laboratories Record of Decision, Federal Register, February 2, 2006. http://a257.g.akamaitech.net/7/257/2422/01jan20061800/edocket.access.gpo.gov/2006/E6-1402.htmJ.D. Miller, "Sparks fly on Boston lab plan," The Scientist, May 5, 2004. http://www.the-scientist.com/article/display/22154/Stop the Bioterrorism Lab, Alternatives in Community and Environment http://www.ace-ej.org/BiolabWeb/biolab.htmlC. Kittredge, "BU BSL-4 lab faces more scrutiny," The Scientist, January 24, 2005. http://www.the-scientist.com/article/display/22576/"Thomas Moore named acting provost at BUMC," BU Bridge, March 19, 2004. http://www.bu.edu/bridge/archive/2004/03-19/moore.htmlS. Smith, "Bacterium infected 3 at BU biolab," Boston Globe, January 19, 2005 http://www.boston.com/news/local/articles/2005/01/19/bacterium_infected_3_at_bu_biolab/ Sheldon Krimsky http://www.tufts.edu/~skrimsky/bio.htm

NIH OKs embattled Boston biolab

The Scientist ARCHIVES

Become a Member of

Meet the Author

John Dudley Miller

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform